Clinical trial NCT04332640: Clinical Evaluation of the Next Generation Phaco System
Official title: Clinical Investigation of the Next Generation Phaco System (VERITAS Vision System)
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Cataract
Lead sponsor: Johnson & Johnson Surgical Vision, Inc.
Sponsor class: INDUSTRY
First posted: 2020-04-02
Enrollment: 79
Sex: ALL
Minimum age (years): 22
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: This study is a prospective, open-label clinical study of the VERITAS Vision System.

The study will be conducted at up to three sites, with minimum 55 eyes and up to 150 eyes to be treated. The investigator or designee will perform the cataract surgery with the VERITAS Vision System on the subjects. The data from the system log files, the questionnaire, the operative report and other medical records will be used to assess the clinical utilization of the VERITAS Vision System.


Eligibility criteria: Inclusion Criteria:

* Minimum 22 years of age.
* Cataracts for which cataract extraction and posterior chamber IOL implantation have been planned.
* Availability, willingness, ability and sufficient cognitive awareness to comply with study requirements, examination procedures, and visits.
* Be willing to provide informed consent and authorization to disclose protected health information or equivalent documentation necessary to comply with applicable privacy laws pertaining to medical procedures in the governing countries.

Exclusion Criteria:

* Expected surgical difficulties at the time of cataract extraction, which may increase the potential for complications (e.g., persistent bleeding, significant iris damage, uncontrolled intraocular pressure change, or significant vitreous prolapse or loss).
* Subjects with only one good eye (e.g. amblyopic condition etc.).
* Subjects with conditions associated with increased risk of zonular rupture, including capsular or zonular abnormalities that may lead to IOL decentration, including pseudoexfoliation, trauma, or posterior capsule defects.
* History or current use of alpha-1 antagonist medication (e.g., Flomax).
* Any condition which, in the Investigator's opinion, would make it unsafe (for the subject or for the study personnel) to treat the subject as part of this research study or for which cataract surgery is contraindicated.
* Pupil abnormalities (non-reactive, fixed pupils, or abnormally shaped pupils).
* Is pregnant, or is breast feeding, or intend to become pregnant during the study.
* Concurrent participation or expected participation in an interventional (i.e., surgical or pharmaceutical interventional) clinical trial within 14 days prior to study screening.

Primary outcomes:
measure: Proportion of Eyes With Surgeon Satisfaction Rating Score of 4 or 5
timeFrame: 1 day postoperative
Secondary outcomes:
Other outcomes:
Locations:
city: Bakersfield
country: United States
facility: ACE Eyecare, Inc
state: California
city: El Escalón
country: El Salvador
facility: Grupo Oftalmo & Plastico, Centro de Oftalmologia y Cirugia Plastica
state: San Salvador
Study officials:
affiliation: Johnson & Johnson Surgical Vision
name: Johnson & Johnson Surgical Vision Clinical Trial
role: STUDY_DIRECTOR
References: